Humoral and cellular response to spike of delta sars-cov-2 variant in vaccinated patients with multiple sclerosis

HIGHLIGHTS

• who: Delia Goletti from the Duke University, United States have published the research: Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis, in the Journal: (JOURNAL)
• what: The authors assessed the cellular response against Delta SARS-CoV-2 variant following COVID-19 vaccination in patients with MS treated with the following DMTs: antiCD20 (i.e., ocrelizumab), sphingosine-1-phosphate receptor modulators (i.e., fingolimod), synthetic purine nucleoside (i.e., cladribine) and immunomodulators (i.e .
• how: The results were analyzed using GraphPad software (GraphPad Prism . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.